#ASCO2022 Jones FAKTION randomized phase 2 of fulvestrant +\- AKT inhibitor capivasertib. Addition of capivasertib increases PFS of 10.3 vs 4.8 mo. OS 29.3 vs 23.1 mo. Biomarker NGS results showed pathway alterations in 25% of pts.